Metformin-Derived Hybrid Molecules for Glioblastoma Treatment

Caroline Delehedde, Mathieu Chocry, Sophie Thétiot-Laurent, Françoise Garrouste, Marcel Culcasi, Hervé Kovacic, Sylvia Pietri

To cite this version:

Caroline Delehedde, Mathieu Chocry, Sophie Thétiot-Laurent, Françoise Garrouste, Marcel Culcasi, et al.. Metformin-Derived Hybrid Molecules for Glioblastoma Treatment. Proceedings, MDPI, 2019, 22 (1), pp.83. 10.3390/proceedings2019022083. hal-02393327

HAL Id: hal-02393327
https://hal-amu.archives-ouvertes.fr/hal-02393327
Submitted on 5 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Abstract
Metformin-Derived Hybrid Molecules for Glioblastoma Treatment †

Caroline Delehedde 1,*, Mathieu Chocry 1,2, Sophie Thétiot-Laurent 1, Françoise Garrouste 2, Marcel Culcasi 1, Hervé Kovacic 2 and Sylvia Pietri 1

1 Aix Marseille Univ, CNRS, UMR 7273, ICR, SMBSO, 13013 Marseille, France
2 Aix Marseille Univ, CNRS, UMR 7051, INP, 13005 Marseille, France
* Correspondence: caroline.delehedde@univ-amu.fr
Published: 19 August 2019

Keywords: metformin; phenolics; hybrid molecules; glioblastoma; cytotoxicity; oxidative stress

Glioblastoma is the most common cerebral tumor in adults. The median survival of glioblastoma patients is 12 months. Metformin is a biguanide used as a standard clinical drug for the treatment of type 2 diabetes. Recently, several studies revealed that the risk of cancer development was significantly reduced for diabetic patients treated with metformin compared to those treated with insulin or sulfonylureas [1]. Even if metformin acts as an antitumoral agent, it is a nontoxic molecule with IC50 around 10 mM in cancer cells. In cancer research, naturally occurring phenolic acids are well known to be useful antioxidant agents and allow the inhibition of the migration and adhesion of cancer cells [2]. Moreover, a recent study [3] on nitrones combined with phenolic acids has shown that phenolic acids keep their antioxidant properties even if they are coupled with another molecule. The purpose of this study is to design new molecules combining metformin and a phenolic acid to improve the cytotoxicity on cancer cells.

A series of hybrid molecules was then synthesized. For each molecule, IC50 on glioblastoma cell lines (U87 and U251) and on human dermal fibroblasts was tested. After this first screening, the mechanisms through which the best hybrid molecules act on cancer cells were studied and compared with those of metformin. Finally, the study of cytotoxicity on cancer stem cells of glioblastoma, GBM6, and GBM9 revealed that metformin-derived molecules may also restrict the growth of stem cells. As cancer stem cells are one of the causes of tumor resistance [4], metformin hybrid molecules may become a novel therapeutic option to treat glioblastoma.

References

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).